Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

May 21 2010NewsGuard 100/100 Score

Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois. The presentation will highlight data from Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients who have been retreated upon relapse after discontinuing previous brentuximab vedotin therapy.

Details of the ASCO presentation are below and the full abstract is available on the ASCO website at www.asco.org.

"Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series"

  • Saturday, June 5, 2010, 8:00 a.m. to 12:00 p.m. Central Time
  • Abstract # 8062
  • Poster session: Lymphoma and plasma cell disorders
  • First author: Dr. Nancy L. Bartlett, Siteman Cancer Center, Washington University, St. Louis, Missouri
Source:

Seattle Genetics and Millennium: The Takeda Oncology Company

Posted in: Drug Trial News | Medical Procedure News | Medical Condition News

Tags: , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Duke-NUS team develops test to monitor engineered T cells in cancer treatment
Rare variant analysis reveals genetic spectrum of monogenic diabetes genes
Barcoding small extracellular vesicles with new CRISPR-based system
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer
Study sheds light on how cells repair damaged DNA
Liver cell aging can trigger multi-organ failure
Researchers discover how mutations disrupt protein splicing and cause disease
SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Researchers reveal cellular foundations of functional brain networks in humans